Background -Although the bronchodilating effect of inhaled anticholinergics has been established in patients with chronic obstructive pulmonary disease (COPD), their effects on exercise capacity are still controversial. Previous studies have suggested that the standard dosage hardly affects exercise tolerance, whereas higher doses might elicit an improvement. The aim of the present study was to determine the dose of ipratropium bromide aerosol that improves exercise performance using progressive cycle ergometry in patients with stable COPD. 
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Background -Although the bronchodilating effect of inhaled anticholinergics has been established in patients with chronic obstructive pulmonary disease (COPD), their effects on exercise capacity are still controversial. Previous studies have suggested that the standard dosage hardly affects exercise tolerance, whereas higher doses might elicit an improvement. The aim of the present study was to determine the dose of ipratropium bromide aerosol that improves exercise performance using progressive cycle ergometry in patients with stable COPD. Methods -Twenty men with stable COPD of mean (SD) age 69-2 (4.6) years and forced expiratory volume in one second (FEVy) 1-00 (0.37) 1 were studied in a randomised double blind manner. Each patient received ipratropium bromide in doses of 240 ig, 160 jg, 80 pg, 40 jg, and placebo from a metered dose inhaler (MDI) with an InspirEase spacer on five separate days. Spirometric parameters were assessed before and at 30, 60, 90 , and 120 minutes after each inhalation, and pulse rate and blood pressure were also measured immediately before each spirometric measurement. Symptom limited progressive (20 watts/min) cycle ergometer exercise tests were performed 90 minutes after each inhalation. Results -Ipratropium bromide in doses of 160 ig and 240 jg produced a greater increase in FEV1 than 40 ig or 80 ig ipratropium bromide at all time points. Doses of 160 pg and 240 jg ipratropium bromide also produced greater increases in maximal work load and maximal oxygen consumption than placebo, whereas 40 jg and 80 ig ipratropium bromide did not.
There was a weak correlation between the change in FEV, and the change in maximal work load (r=0.45). No differences were found in pulse rate or blood pressure between the treatment and placebo groups, and no side effects were noted throughout the study. Conclusions -A dose of at least four times the standard dose of ipratropium bromide from an MDI with a spacer device was necessary to improve maximal cycle exercise capacity in patients with stable COPD. Although the data from cycle ergometry cannot be directly applied to exercise performed during day to day activities, it is conceivable that the recommended doses of ipratropium bromide do not elicit the optimal clinical benefits.
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The goal oftreatment ofchronic obstructive pulmonary disease (COPD) with bronchodilators is to improve airways obstruction and to improve exercise tolerance. While the dilating effect of inhaled bronchodilators in patients with COPD has been established,'-5 their effects on exercise capacity are still controversial. To date, several studies have examined the relationship between short term bronchodilator response and exercise capacity,6-l0 but only a few studies have shown that exercise capacity, assessed using cycle ergometry, is improved by an inhaled anticholinergic agent. In each study only a single small dose of an inhaled anticholinergic was evaluated, and the results suggested that the standard dosage hardly affects exercise tolerance whereas higher doses might elicit an improvement.
The purpose of the present study was to determine the dose of ipratropium bromide that produces the maximum improvement in exercise performance, evaluated by progressive cycle ergometry, and also to determine if there is a significant relationship between this improvement in airways obstruction and exercise capacity in patients with COPD. age. Exercise data were recorded using an automated exercise testing system (Desktop Diagnostics/CPX, Medical Graphic Corporation, St Paul, USA) which converts breathby-breath analog input to digital form in an on-line fashion. The testing system included a pneumotachograph with a gas analyser module and a personal computer interfaced to the measuring instrument. Minute ventilation (VE) and oxygen and carbon dioxide tensions in the expired air were determined every eight breaths, and from these measurements the mean VE, oxygen uptake (Vo,), and carbon dioxide production (Vco2) were rapidly calculated. Routine volume calibration was accomplished with a three litre syringe. A gas analyser was calibrated just before the study with air and a standard reference gas mixture (15% oxygen, 5% carbon dioxide). Arterial oxygen saturation (Sao2) was measured by pulse oximetry (N-200 pulse oximeter, Nellcor Inc, Hayward, USA), and heart rate (HR) and waveform were measured by electrocardiography (Life Scope 8, Nihon Koden Co, Tokyo, Japan). At the end of each exercise test symptoms of leg effort and breathlessness were scored with the Borg scale (0 to 10), which was presented within easy vision of the subject. None The drug doses were given in random order. The spacer attached MDI was held in the mouth and, after the patient had exhaled to functional residual capacity, the canister was activated. Patients inhaled very slowly until total lung capacity was reached, and then the breath was held for at least ten seconds. To ensure that the drugs were administered always in the same way, the inhalation technique was carefully observed by the same doctor (AI) who (fig 3) . The data represent the differ- This study was partly supported by a research grant from the Smoking Research Foundation of Japan. The authors thank Drs Naoharu Sugiura, Hideo Kita, and Kenzo Kawakami for performing the body plethysmography and Nippon Boehringer Ingelheim Co. for providing the matching placebo of ipratropium bromide.
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